摘要
目的建立结直肠癌裸鼠移植肿瘤模型,用小动物18F-FDG PET/CT技术评价西妥昔单抗对人结直肠癌移植肿瘤的影响。方法BALB/c裸鼠皮下分别接种人结直肠癌细胞HCT116、LIM1215,建立HCT116与LIM1215两种荷瘤裸鼠模型。将成瘤后的模型分为对照组和西妥昔单抗治疗组(n=5),并且全程观察肿瘤体积变化情况。给药1周后采用小动物18F-FDG PET/CT技术评价实体肿瘤模型,并测量各组织与器官的18F-FDG最大每克组织摄取率。结果小动物18FFDG PET/CT成像显示裸鼠接种部位肿瘤内放射性摄取值增高,LIM1215与HCT116肿瘤模型的治疗组与对照组相比,肿瘤/组织或器官18F-FDG摄取比率均普遍降低,其中肿瘤/颈肌、肿瘤/心脏与肿瘤/肝脏比值差异有统计学意义(P=0.047、0.008、0.024),但两种肿瘤模型的肿瘤体积测量结果均显示,治疗组与对照组的肿瘤生长趋势差异无统计学意义。结论在西妥昔单抗对结直肠癌裸鼠移植肿瘤模型的治疗实验中,西妥昔单抗对肿瘤生长尚未有明显抑制作用时,小动物18F-FDG PET/CT可监测到肿瘤葡萄糖代谢的变化。
Objective To observe the effect of cetuximab in tumor with small animal PET/CT by establishing the xenogenous implant model of colorectal cancer in nude mice. Methods HCT116 and LIM1215 tumor-bearing nude mouse models were developed by subcutaneous implantation of HCT116 and LIM1215 cells into BALB/c-nu mice. The tumor models were divided into the control group and cetux-imab treatment group （n=5）, and to observe the growth of tumor. Then the tumor models were evaluated by small animal 18F-FDG PET/CT after one week, and we measured the maximum percentage injected dose per gram from tissue and organ at the same time. Results The uptake of 18F-FDG in tumor tissues was significantly higher than that in normal tissues. Compared with control group, the 18F-FDG uptake rates of tumors/tissue or organ were generally lower in treatment group, which had significant difference in the ratio of tumor/neck, tumor/tumor and heart/liver （P=0.047、0.008、0.024）. But the growth trends of tumor vol-ume had no significant difference between treatment group and control group. Conclusion Small animal 18F-FDG PET/CT can monitor the change of glucose metabolism in tumor, while there is no obvious in-hibitory effect in tumor growth with cetuximab treating xenogenous implant nude mice of colorectal cancer.
出处
《中华普通外科学文献（电子版）》
2015年第3期14-17,共4页
Chinese Archives of General Surgery(Electronic Edition)
基金
广东省科技计划资助项目(2010B060500007)
